Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Feb 11;310(6976):353–357. doi: 10.1136/bmj.310.6976.353

Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening.

Z H Miedzybrodzka 1, M H Hall 1, J Mollison 1, A Templeton 1, I T Russell 1, J C Dean 1, K F Kelly 1, T M Marteau 1, N E Haites 1
PMCID: PMC2548760  PMID: 7866213

Abstract

OBJECTIVE--To perform a rigorous comparative evaluation of stepwise and couple approaches to antenatal carrier screening for cystic fibrosis. DESIGN--Pragmatic randomised trial. SETTING--Hospital antenatal clinic serving a regional population. SUBJECTS--2002 women (couples) attending for booking antenatal visit at less than 17 weeks' gestation with no family history of cystic fibrosis. INTERVENTIONS--Offering counselling and carrier testing for cystic fibrosis, either to women in the first instance (stepwise) or to couples (couple screening). MAIN OUTCOME MEASURES--Uptake rates; anxiety; knowledge of cystic fibrosis and carrier status (both partners); attitudes to health, pregnancy, the baby, and screening (both partners); and uptake of carrier testing by relatives. RESULTS--Uptake of screening was the same for both approaches (90%). After delivery most women remembered test results and their meaning, but 53/253 (21%) of those with negative results of couple testing had forgotten that repeat testing would be advisable if they had a pregnancy with a new partner. With stepwise screening women identified as carriers had high levels of anxiety when results were received (mean anxiety score 52.3). This dissipated with a reassuring partner's result (carriers' mean anxiety score 36.1) to levels similar to those receiving negative results from couple screening. Of those receiving negative results, women who had stepwise screening were significantly less anxious than those who had couple screening (mean score with result 32.1 v 35.4, 95% confidence interval for difference -4.7 to -2.1). CONCLUSIONS--Couple screening allows carriers to avoid transient high levels of anxiety, but is associated with more anxiety and false reassurance among most screenees who will test negative. Stepwise screening gives carriers and their relatives genetic information and is, in our opinion, the better method.

Full text

PDF
353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bekker H., Modell M., Denniss G., Silver A., Mathew C., Bobrow M., Marteau T. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ. 1993 Jun 12;306(6892):1584–1586. doi: 10.1136/bmj.306.6892.1584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cutting G. R., Kasch L. M., Rosenstein B. J., Zielenski J., Tsui L. C., Antonarakis S. E., Kazazian H. H., Jr A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990 Jul 26;346(6282):366–369. doi: 10.1038/346366a0. [DOI] [PubMed] [Google Scholar]
  3. Harris H., Scotcher D., Hartley N., Wallace A., Craufurd D., Harris R. Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ. 1993 Jun 12;306(6892):1580–1583. doi: 10.1136/bmj.306.6892.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Henshaw R. C., Naji S. A., Russell I. T., Templeton A. A. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ. 1993 Sep 18;307(6906):714–717. doi: 10.1136/bmj.307.6906.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kerem B. S., Zielenski J., Markiewicz D., Bozon D., Gazit E., Yahav J., Kennedy D., Riordan J. R., Collins F. S., Rommens J. M. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8447–8451. doi: 10.1073/pnas.87.21.8447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kerem B., Rommens J. M., Buchanan J. A., Markiewicz D., Cox T. K., Chakravarti A., Buchwald M., Tsui L. C. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073–1080. doi: 10.1126/science.2570460. [DOI] [PubMed] [Google Scholar]
  7. Lench N., Stanier P., Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet. 1988 Jun 18;1(8599):1356–1358. doi: 10.1016/s0140-6736(88)92178-2. [DOI] [PubMed] [Google Scholar]
  8. Livingstone J., Axton R. A., Gilfillan A., Mennie M., Compton M., Liston W. A., Calder A. A., Gordon A. J., Brock D. J. Antenatal screening for cystic fibrosis: a trial of the couple model. BMJ. 1994 Jun 4;308(6942):1459–1462. doi: 10.1136/bmj.308.6942.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marteau T. M., Kidd J., Cook R., Michie S., Johnston M., Slack J., Shaw R. W. Psychological effects of having amniocentesis: are these due to the procedure, the risk or the behaviour? J Psychosom Res. 1992 May;36(4):395–402. doi: 10.1016/0022-3999(92)90076-e. [DOI] [PubMed] [Google Scholar]
  10. Marteau T. M., van Duijn M., Ellis I. Effects of genetic screening on perceptions of health: a pilot study. J Med Genet. 1992 Jan;29(1):24–26. doi: 10.1136/jmg.29.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mennie M. E., Gilfillan A., Compton M., Curtis L., Liston W. A., Pullen I., Whyte D. A., Brock D. J. Prenatal screening for cystic fibrosis. Lancet. 1992 Jul 25;340(8813):214–216. doi: 10.1016/0140-6736(92)90476-j. [DOI] [PubMed] [Google Scholar]
  12. Miedzybrodzka Z. H., Dean J. C., Russell G., Friend J. A., Kelly K. F., Haites N. E. Prevalence of cystic fibrosis mutations in the Grampian region of Scotland. J Med Genet. 1993 Apr;30(4):316–317. doi: 10.1136/jmg.30.4.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miedzybrodzka Z., Haites N., Hall M., Templeton A., Marteau T., Dean J., Kelly K., Russell I. Antenatal cystic fibrosis carrier screening--whether, when and how? Paediatr Perinat Epidemiol. 1993 Oct;7(4):368–375. doi: 10.1111/j.1365-3016.1993.tb00416.x. [DOI] [PubMed] [Google Scholar]
  14. Schwartz D., Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637–648. doi: 10.1016/0021-9681(67)90041-0. [DOI] [PubMed] [Google Scholar]
  15. Shrimpton A. E., McIntosh I., Brock D. J. The incidence of different cystic fibrosis mutations in the Scottish population: effects on prenatal diagnosis and genetic counselling. J Med Genet. 1991 May;28(5):317–321. doi: 10.1136/jmg.28.5.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wald N. J. Couple screening for cystic fibrosis. Lancet. 1991 Nov 23;338(8778):1318–1319. doi: 10.1016/0140-6736(91)92605-2. [DOI] [PubMed] [Google Scholar]
  17. Watson E. K., Mayall E., Chapple J., Dalziel M., Harrington K., Williams C., Williamson R. Screening for carriers of cystic fibrosis through primary health care services. BMJ. 1991 Aug 31;303(6801):504–507. doi: 10.1136/bmj.303.6801.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zielenski J., Bozon D., Kerem B., Markiewicz D., Durie P., Rommens J. M., Tsui L. C. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10(1):229–235. doi: 10.1016/0888-7543(91)90504-8. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES